Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

4.7K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.7K
Neural Regulation of Blood Pressure01:18

Neural Regulation of Blood Pressure

8.1K
The neural regulation of blood pressure involves intricate interactions between the autonomic nervous system (ANS) and cardiovascular system, ensuring adequate perfusion of tissues. This regulation primarily occurs through baroreceptor and chemoreceptor reflexes, involving both short-term and long-term mechanisms.
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
8.1K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

3.0K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

2.2K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

1.3K
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Cardiac Resynchronization Therapy on Cardiovascular and Noncardiovascular Hospitalization: A MADIT-CRT Long-Term Follow-Up.

Journal of the American Heart Association·2026
Same author

Flecainide for the Treatment of Andersen-Tawil Syndrome.

JACC. Clinical electrophysiology·2025
Same author

Risk Prediction in Male Adolescents With Congenital Long QT Syndrome: Implications for Sex-Specific Risk Stratification in Potassium Channel-Mediated Long QT Syndrome.

Journal of the American Heart Association·2024
Same author

Treating Hypertension in Patients With Orthostatic Hypotension: Benefits vs Harms in the Era of Aggressive Blood Pressure Lowering.

JAMA·2023
Same author

Team-based home blood pressure monitoring for blood pressure equity a protocol for a stepped wedge cluster randomized trial.

Contemporary clinical trials·2023
Same author

Intraoperative Ventricular Tachycardia Ablation During Left Ventricular Assist Device Implantation in High-Risk Heart Failure Patients.

Circulation. Arrhythmia and electrophysiology·2022

Related Experiment Video

Updated: Mar 17, 2026

Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice
09:56

Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice

Published on: February 14, 2021

6.0K

Baroreceptor Stimulation for Resistant Hypertension.

Ayhan Yoruk1, John D Bisognano1, John P Gassler1

  • 1University of Rochester Medical Center, Rochester, New York, USA.

American Journal of Hypertension
|July 23, 2016
PubMed
Summary
This summary is machine-generated.

Resistant hypertension, a condition unresponsive to standard treatments, may be managed by baroreflex activation therapy. This innovative approach modulates the sympathetic nervous system to help control blood pressure.

Keywords:
Barostim neoRheosbaroreflex activation therapyblood pressurecarotid baroreceptor stimulationhypertensionresistant hypertensionsympathetic nervous system.

More Related Videos

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography
07:51

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography

Published on: September 22, 2011

29.6K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

844

Related Experiment Videos

Last Updated: Mar 17, 2026

Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice
09:56

Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice

Published on: February 14, 2021

6.0K
Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography
07:51

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography

Published on: September 22, 2011

29.6K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

844

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Medical Devices

Background:

  • Hypertension (HTN) is a global health crisis, increasing risks for cardiovascular disease and end-organ damage.
  • Treatment-resistant HTN affects patients unresponsive to conventional medications and lifestyle changes.
  • Novel nonpharmacologic therapies are crucial for managing resistant HTN.

Purpose of the Study:

  • To review the role of baroreflex activation therapy (BAT) in managing treatment-resistant hypertension.
  • To explore the mechanism of BAT in modulating the sympathetic nervous system for HTN control.

Main Methods:

  • This review synthesizes current research on baroreflex activation therapy.
  • Focuses on the application of electrical stimulation to baroreceptors.
  • Examines the impact on sympathetic nervous system activity in hypertension.

Main Results:

  • Baroreflex activation therapy shows promise as a nonpharmacologic treatment for resistant HTN.
  • Modulating the sympathetic nervous system via baroreceptor stimulation can lower blood pressure.
  • BAT offers a potential therapeutic avenue for challenging HTN cases.

Conclusions:

  • Baroreflex activation therapy represents a significant advancement in managing resistant hypertension.
  • Further research and clinical application of BAT are warranted for this patient population.
  • This therapy targets the sympathetic nervous system's role in circulatory physiology.